Clopidogrel Bisulfate Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 75 mg, 300 mg
Reference Brands: Plavix(US & EU)
Category:
Blood Disorder
Clopidogrel inhibits the P2Y12 receptor on platelets, preventing ADP-induced activation and aggregation. It reduces the risk of blood clots, stroke, and heart attack, providing effective antiplatelet therapy. Benefits include oral administration, proven efficacy in cardiovascular prevention, and long-term safety for patients at risk of thrombotic events.
Clopidogrel Bisulfate tablet is available in Tablet
and strengths such as 75 mg, 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Clopidogrel Bisulfate tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Clopidogrel Bisulfate tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Clopidogrel is approved in both the US by the FDA and in the EU through EMA authorization for preventing blood clots in cardiovascular disease. Regulatory approval requires a detailed dossier demonstrating safety, efficacy, pharmacovigilance, and manufacturing quality. In the US, approval involves submission of comprehensive clinical data, while the EU mandates adherence to regional guidelines, including stability and bioequivalence studies. For guidance on dossier preparation, regulatory strategies, and successful market entry, visit PharmaTradz. Ensuring regulatory compliance is essential for the effective and safe commercialization of clopidogrel tablets worldwide, supporting cardiovascular patient care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing